Scott Ullem Net Worth

The estimated Net Worth of Scott B. Ullem is at least 6.04 百万$ dollars as of 20 June 2024. Mr. Ullem owns over 5,625 units of Edwards Lifesciences Corp stock worth over 2,469,695$ and over the last 11 years he sold EW stock worth over 0$. In addition, he makes 3,571,070$ as Chief Financial Officer、 Corporate Vice President at Edwards Lifesciences Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Ullem EW stock SEC Form 4 insiders trading

Scott has made over 44 trades of the Edwards Lifesciences Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 5,625 units of EW stock worth 254,700$ on 20 June 2024.

The largest trade he's ever made was exercising 80,700 units of Edwards Lifesciences Corp stock on 10 May 2023 worth over 2,840,640$. On average, Scott trades about 8,080 units every 30 days since 2014. As of 20 June 2024 he still owns at least 36,186 units of Edwards Lifesciences Corp stock.

You can see the complete history of Mr. Ullem stock trades at the bottom of the page.

Scott Ullem biography

Scott B. Ullem serves as Chief Financial Officer, Corporate Vice President of the Company. Mr. Ullem became Corporate Vice President, Chief Financial Officer in January 2014. In addition, Mr. Ullem has executive responsibility for the Company’s information technology, information security and corporate services teams. Prior to joining Edwards, he served from May 2010 to December 2013 as Chief Financial Officer of Bemis Company Inc., a Fortune 500 publicly traded global supplier of packaging and pressure sensitive materials used in leading food, consumer, and healthcare products. Mr. Ullem also had leadership responsibility for one of Bemis’ three business segments and the company’s information technology function. Before joining Bemis, Mr. Ullem spent 17 years in investment banking, serving as Managing Director at Goldman Sachs and later at Bank of America. He has served on the Board and Compensation Committee of Berry Global Inc. since 2016 and is a Henry Crown Fellow at the Aspen Institute

What is the salary of Scott Ullem?

As the Chief Financial Officer、 Corporate Vice President of Edwards Lifesciences Corp, the total compensation of Scott Ullem at Edwards Lifesciences Corp is 3,571,070$. There are 1 executives at Edwards Lifesciences Corp getting paid more, with Michael Mussallem having the highest compensation of 11,521,000$.

How old is Scott Ullem?

Scott Ullem is 53, he's been the Chief Financial Officer、 Corporate Vice President of Edwards Lifesciences Corp since 2014. There are 20 older and 1 younger executives at Edwards Lifesciences Corp. The oldest executive at Edwards Lifesciences Corp is William Link, 74, who is the Independent Director.

What's Scott Ullem's mailing address?

Scott's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.

Insiders trading at Edwards Lifesciences Corp

Over the last 21 years, insiders at Edwards Lifesciences Corp have traded over 94,964,396$ worth of Edwards Lifesciences Corp stock and bought 47,398 units worth 3,992,090$ . The most active insiders traders include Michael A Mussallem、Donald E Jr Bobo、Steven R Loranger. On average, Edwards Lifesciences Corp executives and independent directors trade stock every 8 days with the average trade being worth of 1,126,057$. The most recent stock trade was executed by Donald E Jr Bobo on 11 September 2024, trading 5,000 units of EW stock currently worth 226,400$.

What does Edwards Lifesciences Corp do?

edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.

Complete history of Mr. Ullem stock trades at Illumina Inc、Berry Global Inc、Edwards Lifesciences Corp

Edwards Lifesciences Corp executives and stock owners

Edwards Lifesciences Corp executives and other stock owners filed with the SEC include:

• Michael Mussallem,
  Chairman of the Board, Chief Executive Officer
• Scott Ullem,
  Chief Financial Officer, Corporate Vice President
• Larry Wood,
  Corporate Vice President - Transcatheter Aortic Valve Replacement
• Donald Bobo,
  Corporate Vice President - Strategy and Corporate Development
• Catherine Szyman,
  Corporate Vice President - Critical Care
• Jean-Luc Lemercier,
  Corporate Vice President - EMEA (Europe, Middle East and Africa)
• Michael A. Mussallem,
  Chairman & CEO
• Jean-Luc Lemercier,
  Corp. VP of Europe, Middle East, Africa, Canada & Latin America
• Scott B. Ullem,
  Corp. VP & CFO
• Larry L. Wood,
  Corp. VP of Transcatheter Aortic Valve Replacement
• Donald E. Bobo Jr.,
  Corp. VP of Strategy & Corp. Devel.
• Heisz Stone,
  Independent Director
• William Link,
  Independent Director
• Kieran Gallahue,
  Independent Director
• Steven Loranger,
  Independent Director
• Nicholas Valeriani,
  Independent Director
• Martha Marsh,
  Lead Independent Director
• Paul LaViolette,
  Director
• Ramona Sequeira,
  Director
• Daveen Chopra,
  Corporate Vice President - Surgical Structural Heart
• Huimin Wang,
  Corporate Vice President - Japan, Asia and Pacific
• Christine Z. McCauley,
  Corp. VP of HR
• Dirksen J. Lehman,
  Corp. VP of Public Affairs
• Arnold A. Pinkston,
  Corp. VP & Gen. Counsel
• Mark Wilterding,
  VP of Investor Relations
• Dr. Todd J. Brinton,
  Corp. VP of Advanced Technology & Chief Scientific Officer
• Patrick B Verguet,
  CVP, Europe
• John T Cardis,
  Director
• Schack Wesley W Von,
  Director
• Daniel J. Lippis,
  CVP, JAPAC
• Carlyn D Solomon,
  CVP, Critical Care & Vascular
• David E I Pyott,
  Director
• Michael R Bowlin,
  Director
• Bruce P Garren,
  Corp VP, Gen Counsel & Secty
• Barbara J Mcneil,
  Director
• Robert Alexander Ingram,
  Director
• John H Jr Kehl,
  Corp VP, Strategy & Bus Dev
• Thomas M Abate,
  CVP, CFO and Treasurer
• Christine Z Mc Cauley,
  CVP, Human Resources
• Robert C Reindl,
  Corp VP, Human Resources
• Aimee S Weisner,
  CVP, General Counsel
• Vernon R Jr Loucks,
  Director
• Paul C Redmond,
  CVP, CardioVations Surgcl Sys
• Corinne H Nevinny,
  CVP, Chief Financial Officer
• Philip M Neal,
  Director
• Stuart L Foster,
  Corp VP, Technology/Discovery
• John Alexander Martin,
  CVP, North America
• Anita Bessler,
  Corp VP, Global Franchise Mgmt
• Randel William Woodgrift,
  Corp VP, Manufacturing Ops
• J Randall Nelson,
  Corp VP, North America
• David T Feinberg,
  Director
• Robert W.A. Sellers,
  SVP, Corporate Controller
• Bernard J Zovighian,
  CEO
• Wayne Markowitz,
  GM & SVP, Surgical
• Leslie C. Davis,
  Director